aplastic anemia | Page 52 | Aplastic Anemia & MDS International Foundation

aplastic anemia

Maria Baer, MD

Baer, Maria
Director, Hematologic Malignancies Program
University of Maryland Greenebaum Comprehensive Cancer Center

Maria Baer joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, Maryland in 2007 as director of hematologic malignancies and professor of medicine and molecular medicine, University of Maryland School of Medicine. She previously served as chief of the leukemia section at Roswell Park Cancer Institute and professor of medicine and associate professor of molecular pharmacology and cancer therapeutics at the University at Buffalo School of Medicine and Biomedical Sciences in Buffalo, New York.

A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.

Author(s): 
Kim H, Lee JH, Joo YD, Bae SH, Hyun MS, Lee JH, Kim DY, Lee WS, Ryoo HM, Kim MK, Park JH, Lee KH; Cooperative Study Group A for Hematology (COSAH).
Primary Author: 
Kim H
Journal Title: 
Ann Hematol.
Original Publication Date: 
Apr 2012

Abstract

Bone Marrow Diseases: 

Classification of childhood aplastic anemia and myelodysplastic syndrome

Author(s): 
Niemeyer CM, Baumann I
Primary Author: 
Niemeyer CM
Journal Title: 
Hematology Am Soc Hematol Educ Program
Original Publication Date: 
Dec 2011

Hypoplastic BM disorders in children and adolescents comprise a broad spectrum of disorders. Acquired severe

Long-term follow-up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning

Author(s): 
Konopacki J, Procher R, Robin M, Bieri S, Cayuela JM, Larghero J, Xhaard A, Andreoli AL, Dhedin N, Petropoulou AD, Rodriguez-Otero P, Ribaud P, Moins-Teisserenc H, Carmagnat M, Toubert A, Chalandon Y, Socie' G, Peffault de Latour R
Primary Author: 
Konopacki J
Journal Title: 
Haematologica
Original Publication Date: 
Dec 2011

Background. Due to increased rates of secondary solid organ cancer in patients with severe

Bone Marrow Diseases: 

Functional characterization of CD4+ T cells in aplastic anemia

Author(s): 
Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, Abellan PP, Veen C, Constantini B, Kulasekararaj AG, Benson-Quarm N, Seidl T, Mian SA, Farzaneh F, Mufti GJ
Primary Author: 
Kordasti S
Journal Title: 
Blood
Original Publication Date: 
Dec 2011

he role of CD4(+) T-cells in the pathogenesis of AA is not well characterized. The focus of this study is to investigate the role of CD4(+) T-cells in AA with particular emphasis on CD4(+) regulatory and effector T-cell subsets and correlation with disease severity. 63 patients(48 at diagnosis) with acquired AA were studied. Numbers of Th1 and Th2-cells were significantly higher in AA compared with age matched healthy donors (HDs) (p=0.03) (p=0.006).

Bone Marrow Diseases: 

Survival After Immunosuppressive Therapy in Children with Aplastic Anemia

Author(s): 
Nair V, Sondhi V, Sharma A, Das S, Sharma S
Primary Author: 
Nair V
Journal Title: 
Indian Pediatr
Original Publication Date: 
Oct 2011

OBJECTIVE:

To determine the survival of children ?18y, treated with immunosuppresive therapy (IST) using equine antithymocyte globulin (e-ATG) and cyclosporine(CsA).
DESIGN:

Prospective data entry as per a specified format.
SETTING:

Tertiary care hospital.
PATIENTS:

From January 1998 to December 2009, 40 children were diagnosed with acquired aplastic anemia; 33 patients, who received IST, were analyzed. 31 children (94%) received one course of e-ATG and CsA. 2 patients (6%) received two courses of ATG.
INTERVENTION:

Immunosuppressive therapy using equine ATG and cyclosporine.
MAIN OUTCOME MEASURES:

Overall response and overall survival.
RESULTS:

Bone Marrow Diseases: